scholarly journals Progressive Myoclonic Epilepsy: Review Article with A Case Report of Lafora Disease

2018 ◽  
Vol 42 (3) ◽  
pp. 138-147
Author(s):  
Selina Husna Banu ◽  
Mashaya Zaman Koli

Progressive myoclonic epilepsy (PME) is an autosomal recessive, apparently a rare complex epilepsy syndrome. Among different types of PME, lafora body disease is more quickly progressive usually fatal within 2nd and 3rd decade. They are characterized by childhood or adolescent onset difficult to control multiple type seizures including myoclonous, generalized tonic clonic, absences, psychomotor regression with ataxia, dementia, dysarthria, visual hallucinations, and other general features. Early suspicion is important that leads to the rational diagnostic workout. The electro-clinical criteria would help a lot to exclude the benign epilepsy syndrome such as juvenile myoclonic epilepsy (JME) and suspect PME at the early stage of the complex epilepsy syndrome. Diagnosis is further clarified and confirmed by finding lafora body in skin and genetic study. Genetic mutation found in more than 87% cases in EPM2A gene or the EPM2B also known as NHLRC1 gene and are inherited in an autosomal recessive manner. EMP2A gene is located on chromosome 6q24. They are reported from Mediterranean basin, central Asia, India, Pakistan, northern Africa and Middle East where consanguineous marriage is common. We report a diagnosed case for the first time in Bangladesh. With the detail clinical history, rational use of the available investigation tools and clinical suspicion, diagnosis of the disorder at its early stage is possible. The rapid progress in genetic therapy would be a great hope in near future. Bangladesh J Child Health 2018; VOL 42 (3) :138-147

2018 ◽  
Vol 07 (01) ◽  
pp. 021-023
Author(s):  
Fatma Feki ◽  
Chahnez Triki ◽  
Nesrine Amara

AbstractJuvenile Huntington's disease (JHD) shares many general clinical features with the adult form. One important difference is that JHD patients experience more epileptic manifestations, sometimes difficult to control. We describe an atypical clinical picture of a genetically confirmed JHD patient diagnosed during evaluation for a progressive myoclonic epilepsy. A female patient with a family history of psychiatric disorders developed recurrent drug-resistant myoclonic seizures at the age of 6 years, followed by extrapyramidal symptoms (rigidity and dystonia). Cognitive impairment, akinetic rigidity syndrome, and dystonia were noticed at the age of 10 years. Epileptiform abnormalities were noted in ictal electroencephalography. Magnetic resonance imaging showed brain atrophy. Genetic testing for HD confirmed the diagnosis. JHD can initially manifest as myoclonic epilepsy. A DNA testing should be performed if clinical history is suggestive.


2011 ◽  
Vol 15 ◽  
pp. S107
Author(s):  
Ö. Bektas ◽  
A. Yilmaz ◽  
S. Teber ◽  
E. Aksoy ◽  
G. Deda

2014 ◽  
Vol 290 (2) ◽  
pp. 841-850 ◽  
Author(s):  
Anna A. DePaoli-Roach ◽  
Christopher J. Contreras ◽  
Dyann M. Segvich ◽  
Christian Heiss ◽  
Mayumi Ishihara ◽  
...  

2010 ◽  
Vol 2010 (nov04 1) ◽  
pp. bcr0120102653-bcr0120102653 ◽  
Author(s):  
M. Hashmi ◽  
F. Saleem ◽  
M. S. Mustafa ◽  
M. Sheerani ◽  
Z. Ehtesham ◽  
...  

2013 ◽  
Vol 1 ◽  
pp. 118-121 ◽  
Author(s):  
Kathrin Schorlemmer ◽  
Sebastian Bauer ◽  
Marcus Belke ◽  
Anke Hermsen ◽  
Karl Martin Klein ◽  
...  

1992 ◽  
Vol 7 (1_suppl) ◽  
pp. S41-S50 ◽  
Author(s):  
Generoso G. Gascon ◽  
Pinar T. Ozand ◽  
Robert E. Erwin

A sister and brother, now aged 7 and 9 years, presented with developmental arrest, gait disturbance, dementia, and a progressive myoclonic epilepsy syndrome with hyperacusis in the second year of life. Then, spastic quadriparesis led to a decerebrate state. In the absence of macular or retinal degeneration, organomegaly, and somatic-facial features suggesting mucopolysaccharidosis, the presence of hyperacusis together with sea-blue histiocytes in bone marrow biopsies and deficient β-galactosidase activity but normal glucosidase, hexosaminidase, and neuraminidase activity on lysosomal enzyme assays constitutes the clinical-pathologic-biochemical profile of GM1 gangliosidosis type 2. This is a rare, late infantile onset, progressive gray-matter disease in which β-galactosidase deficiency is largely localized to the brain, though it can be demonstrated in leukocytes and cultured skin fibroblasts. It must be distinguished from the Jansky-Bielschowsky presentation of neuronal ceroid lipofuscinosis, mitochondrial encephalopathy, lactic acidosis, strokelike episodes (MELAS) and myoclonic epilepsy with ragged-red fibers (MERRF) syndromes, atypical presentations of GM2 gangliosidoses (Tay-Sachs and Sandhoff's diseases), primary sialidosis (neuraminidase deficiency), galactosialidosis, and Alpers' disease. (J Child Neurol 1992;7(Suppl):S41-S50.)


2020 ◽  
Vol 13 (12) ◽  
pp. e236971
Author(s):  
Ranjot Kaur ◽  
Neeraj Balaini ◽  
Sudhir Sharma ◽  
Sudarshan Kumar Sharma

Progressive myoclonic epilepsy (PME) is a progressive neurological disorder. Unfortunately, until now, no definitive curative treatment exists; however, it is of utmost importance to identify patients with PME. The underlying aetiology can be pinpointed if methodological clinical evaluation is performed, followed by subsequent genetic testing. We report a case of PME that was diagnosed as Lafora body disease. This case emphasises that, suspecting and identifying PME is important so as to start appropriate treatment and reduce the probability of morbidity and prognosticate the family.


Sign in / Sign up

Export Citation Format

Share Document